Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens

Cancer

Volumn 91, Issue 11, 2001, Pages 2127-2135

  Prescott, James L ^a   Montie, Jim ^b   Pugh, Tom W ^a   McHugh, Terri ^a   Veltri, Robert W ^a  

^a UroCor Incorporated   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bladder carcinoma; Cytology; Mutation; P53 gene; Tumors

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CYTOLOGY; FEMALE; GENE MUTATION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; URINE CYTOLOGY;

AGED; CARCINOMA; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0035370661     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010601)91:11<2127::AID-CNCR1241>3.0.CO;2-R     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Olumi AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am 2000; 27:75-82.
4. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5.
5. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706-9.
6. Vet JA, Hessels D, Marras SA, van de Kaa CA, van der Poel HG, Michalides RJ, et al. Comparative analysis of p53 mutations in bladder washings and histologic specimens. Am J Clin Pathol 1998;110:647-52.
7. Vet JA, Witjes JA, Marras SA, Hessels D, van der Poel HG, Debruyne FM, et al. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res 1996;2:1055-61.
8. Phillips HA, Howard GC, Miller WR. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer 2000;82:136-41.
9. Prescott J, Patel H, Tillman S, McHugh T, Ralph D. Cleavage of double-stranded copy RNA by RNase 1 and RNase T1 provides a robust means to detect p53 gene mutations in clinical specimens. Electrophoresis 1999;20:1149-61.
10. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
11. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-5.
12. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4:829-34.
13. Uchida T, Wada C, Ishida H, Wang C, Egawa S, Yokoyama E, et al. p53 mutations and prognosis in bladder tumors. J Urol 1995;153:1097-104.
14. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079-84.
15. Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000;56: 735-40.
16. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;6:691-700.
17. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000;5: 1854-64.
18. Papanicolaou GN, Marshall VF. Science 1945;101:519.
19. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999;14:1-8.
20. Esrig D, Spruck CH 3d, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
21. Liukkonen TJ, Lipponen PK, Helle M, Jauhiainen KE. Immunoreactivify of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group. Urol Res 1997;25:1-7.